Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
Naquotinib (ASP8273) is a third-generation EGFR inhibitor which binds mutant forms of EGFR, including T790M, thus preventing EGFR-mediated signaling and inducing cell death and growth inhibition of EGFR-overexpressing tumor cells (PMID: 29467275).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Naquotinib||ASP8273||AXL Inhibitor 27 EGFR Inhibitor 3rd gen 20||Naquotinib (ASP8273) is a third-generation EGFR inhibitor that binds mutant forms of EGFR, including T790M, and also inhibits AXL, thus may lead to growth inhibition in tumor cells (PMID: 29467275, PMID: 31092564).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03082300||Phase I||Naquotinib||A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations||Terminated|
|NCT02588261||Phase III||Naquotinib Gefitinib Erlotinib||A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations||Terminated|
|NCT03042013||Phase II||Naquotinib||A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study||Withdrawn|
|NCT02113813||Phase I||Naquotinib||A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations||Completed|
|NCT02674555||Phase I||Naquotinib||A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors||Withdrawn|